Category Archives:

Can training an AI model on copyrighted books ever qualify as fair use? That question of AI training fair use sits at the heart of one of the most consequential copyright disputes of the AI era. On July 20, 2026, the Northern District of California approved a class action settlement awarding a class of copyright holders $1.5 billion against Anthropic PBC, the creators of the Artificial Intelligence Large Language Model (“LLM”) Claude. Continue reading…

When does a generic drug’s “skinny label” cross the line into skinny label patent infringement? For years the answer splintered the lower courts, and the Supreme Court has now resolved it.

Continue reading…

In Versata v. Ford, the U.S. Court of Appeals for the Federal Circuit reinstated an $82.26 million jury award for Versata Software LLC against Ford Motor Company on May 22, 2026. The award had previously been reduced in a 2023 decision by the U.S. District Court for the Eastern District of Michigan, which lowered the breach of contract award from $82.3 million to a nominal $3 and cut a $22.4 million trade secret misappropriation award to $0.

Continue reading…

A patent permanent injunction does not automatically follow a finding of infringement—even a willful one carrying a verdict worth hundreds of millions of dollars. On May 18, 2026, the Eastern District of Texas addressed a Motion for Permanent Injunction by Collision Communications, Inc (“Collision”) seeking to enjoin Samsung Electronics Co., Ltd. and Samsung Electronics America, Inc. (“Samsung”) from infringing U.S. Patent No. 7,593,492 (the “’492 Patent”).

Continue reading…

The Supreme Court is poised to decide one of the most consequential questions in pharmaceutical patent law: when does a generic drug’s marketing create skinny label patent infringement liability? Continue reading…